Drugs / SYN023
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07342257 | Nov 2024 → May 2025 | rabies | Synermore Biologics (Suzhou) Co., Ltd. | Completed | No outcome recorded |
| Phase 1/22 trials · 1 missed | ||||||
| Phase 1/2 | NCT04495569 | Feb → Jun 2019 | rabies | Synermore Biologics (Suzhou) Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT02956746 | Aug 2016 → Dec 2017 | rabies | Synermore Biologics Co., Ltd. | Completed | Missed primary |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT03961555 | Sep 2019 → Dec 2021 | rabies | Synermore Biologics Co., Ltd. | Completed | Met primary |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT04644484 | Sep 2020 → Jun 2022 | Rhabdoviridae infectious disease, rabies | Synermore Biologics (Suzhou) Co., Ltd. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYN023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04644484 ↗ |
| Modality | Monoclonal antibody | “SYN023 (a mixture of two monoclonal antibodies CTB011 and CTB012)” NCT02956746 ↗ |
| Route | Intramuscular | “A single intramuscular injection of SYN023 at 0.3mg/kg” NCT04495569 ↗ |